DK2712625T3 - Vacciner omfattende TB 10.4 - Google Patents

Vacciner omfattende TB 10.4 Download PDF

Info

Publication number
DK2712625T3
DK2712625T3 DK13178000.9T DK13178000T DK2712625T3 DK 2712625 T3 DK2712625 T3 DK 2712625T3 DK 13178000 T DK13178000 T DK 13178000T DK 2712625 T3 DK2712625 T3 DK 2712625T3
Authority
DK
Denmark
Prior art keywords
ala
gly
ag85b
leu
ser
Prior art date
Application number
DK13178000.9T
Other languages
English (en)
Inventor
Jes Dietrich
Claus Aagard
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of DK2712625T3 publication Critical patent/DK2712625T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

Claims (1)

1. Immunogen sammensætning omfattende: a) et fusionsprotein af TB 10.4 proteinet og et Ag85-kompleksprotein, og b) en adjuvans omfattende mindst et polykationisk peptid og mindst et oligonukleotid der er oligo dIC, hvor Ag85-kompleksproteinet et et Ag85B protein, den samlede mængde af TB 10.4 proteinet og Ag85B proteinet er inden for området fra 5,0 til 25,0 pg, og adjuvansen er en blanding af NH2-KLKLLLLLKLK-COOH og 5'-ICI CIC ICI CIC ICI CIC ICI CIC IC-3', til anvendelse som en vaccine mod M. tuberculosis hos et menneske.
DK13178000.9T 2008-07-15 2009-07-14 Vacciner omfattende TB 10.4 DK2712625T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200800997 2008-07-15
EP09776173A EP2320944A1 (en) 2008-07-15 2009-07-14 Vaccines comprising tb10.4

Publications (1)

Publication Number Publication Date
DK2712625T3 true DK2712625T3 (da) 2017-03-13

Family

ID=40243844

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13178000.9T DK2712625T3 (da) 2008-07-15 2009-07-14 Vacciner omfattende TB 10.4

Country Status (6)

Country Link
US (3) US20100015171A1 (da)
EP (2) EP2320944A1 (da)
CN (2) CN102149404A (da)
CA (1) CA2734714C (da)
DK (1) DK2712625T3 (da)
WO (1) WO2010006607A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
CN101790384B (zh) * 2007-06-29 2013-12-11 国立血清研究所 单分枝酰基甘油(mmg)作为佐剂的应用
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
PL2358386T3 (pl) 2008-11-28 2017-04-28 Statens Serum Institut Zoptymalizowane szczepionki na grypę
CN101891825B (zh) * 2010-07-15 2015-01-07 中国人民解放军军事医学科学院生物工程研究所 乙肝核心蛋白与结核抗原或抗原片段的重组融合蛋白及用途
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
IN2014DN05865A (da) * 2011-12-22 2015-05-22 Univ Sydney
WO2013112103A1 (en) * 2012-01-27 2013-08-01 Peas Institut Ab Method of detecting tuberculosis
RU2015109715A (ru) * 2015-03-19 2015-08-20 Общество С Ограниченной Ответственностью "Рд-Биотех" (Ооо "Рд-Биотех") ПРОТИВОТУБЕРКУЛЕЗНАЯ ВАКЦИНА НА ОСНОВЕ РЕКОМБИНАНТНЫХ БЕЛКОВ Ag85B, TB10.4, FliC
RU2647831C1 (ru) * 2017-03-15 2018-03-19 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Вакцина против туберкулеза
CN107496914B (zh) * 2017-08-28 2021-01-01 洛阳赛威生物科技有限公司 一种佐剂组合物及其制备方法和应用
KR20220032054A (ko) 2019-06-14 2022-03-15 스태튼스 세룸 인스티튜트 결핵 백신용 융합 단백질
WO2023156676A1 (en) 2022-02-21 2023-08-24 Statens Serum Institut A novel cationic adjuvant composition

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108745B1 (en) * 1988-08-16 1998-06-30 Univ California Tuberculosis and legionellosis vaccines and methods for their production
US6641814B1 (en) * 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US5955077A (en) * 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
WO1999004005A1 (en) * 1997-07-16 1999-01-28 Institut Pasteur A polynucleotide functionally coding for the lhp protein from mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
EP1200466A2 (en) * 1999-07-13 2002-05-02 Statens Serum Institut Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosisesat-6 gene family
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
AU1657501A (en) 1999-11-12 2001-06-06 Regents Of The University Of California, The Determining the functions and interactions of proteins by comparative analysis
CA2405247A1 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
CA2453173C (en) 2001-07-04 2013-12-10 Health Protection Agency Mycobacterial antigens expressed during latency
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
ATE485056T1 (de) * 2003-03-24 2010-11-15 Intercell Ag Verbesserte impfstoffe
WO2004099771A1 (en) * 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
US6944383B1 (en) * 2004-04-12 2005-09-13 Adc Telecommunications, Inc. Cable management panel with sliding drawer and methods
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
SG159554A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
AU2005338353B2 (en) * 2004-12-01 2011-04-14 Aeras Global Tb Vaccine Foundation Recombinant BCG strains with enhanced ability to escape the endosome
JP5219808B2 (ja) 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
RU2490024C2 (ru) * 2006-06-28 2013-08-20 Статенс Серум Инститьют Расширение спектра т клеток для включения субдоминантных эпитопов путем вакцинации с антигенами, доставленными как белковые фрагменты или пептидные коктейли
WO2008145129A2 (en) * 2007-05-31 2008-12-04 Statens Serum Institut Influenza vaccines
CN101790384B (zh) * 2007-06-29 2013-12-11 国立血清研究所 单分枝酰基甘油(mmg)作为佐剂的应用
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
WO2010009277A2 (en) * 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
EP2344542A2 (en) 2008-09-24 2011-07-20 Adjuvantix Limited Tubercolosis vaccines targeted to cd40

Also Published As

Publication number Publication date
CN107050441A (zh) 2017-08-18
EP2320944A1 (en) 2011-05-18
EP2712625A3 (en) 2014-11-12
CA2734714C (en) 2019-11-12
WO2010006607A1 (en) 2010-01-21
CA2734714A1 (en) 2010-01-21
CN102149404A (zh) 2011-08-10
EP2712625A1 (en) 2014-04-02
US20120014980A1 (en) 2012-01-19
US20100015171A1 (en) 2010-01-21
USRE46583E1 (en) 2017-10-24
US8557258B2 (en) 2013-10-15
EP2712625B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
DK2712625T3 (da) Vacciner omfattende TB 10.4
Van Dis et al. STING-activating adjuvants elicit a Th17 immune response and protect against Mycobacterium tuberculosis infection
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
Morris et al. The immunogenicity of single and combination DNA vaccines against tuberculosis
Belshe et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers
Weinreich Olsen et al. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT‐6 antigen
Agger et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31
Huygen On the use of DNA vaccines for the prophylaxis of mycobacterial diseases
US20200338182A1 (en) Intranasal delivery of a cyclic-di-nucleotide adjuvanted vaccine for tuberculosis
Reed et al. Tuberculosis vaccine development; from mouse to man
Sable et al. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity
US20130101614A1 (en) Novel live recombinant booster vaccine against tuberculosis
Derrick et al. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens
Parlane et al. Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection
Coler et al. Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning
Roche et al. Vaccination with DNA of the Mycobacterium tuberculosis 85B antigen protects mouse foot pad against infection with M. leprae
Mustafa Progress towards the development of new anti-tuberculosis vaccines
Okkels et al. Selecting the components for a safe and efficient tuberculosis subunit vaccine-recent progress and post-genomic insights
Kısa BCG vaccine and new tuberculosis vaccines against mycobacterium tuberculosis: A review
Kumar et al. Immunogenicity Studies with Microbial Fractions of M. tuberculosis H37Rv Total Culture Filtrate
Sarhan Progress in tuberculosis vaccines development
Rahimi et al. A Global Overview of Tuberculosis Vaccine Development
Coler et al. Vaccines Against Mycobacterium tuberculosis: An Overview from Preclinical Animal Studies to the Clinic
Sable et al. Development of subunit vaccine against tuberculosis: Evaluation of secretory proteome of Mycobacterium tuberculosis
Fang et al. Evaluation of the Delivery Modes and Their Effects on the Antigenicity Properties of a Synthetic Multivalent Mycobacterial Gene in Mice